Home » Authors » Nuala Moran

Nuala Moran

Articles

ARTICLES

SkyePharma Exchanges Share Of Phase III Risk, Reward For $30M

Jan. 17, 2001

SkyePharma Exchanges Share Of Phase III Risk, Reward For $30M

Jan. 17, 2001

Avidex Completes £10M Funding For Programs In T-Cell Receptors

Jan. 17, 2001

Cambridge Drug Eyes Licensing Deals Following £7.5M Financing

Jan. 17, 2001

Phytopharm Sees Encouraging Results In Phase I P54 Study

Jan. 10, 2001

Oxford BioMedica Moving To LSE Following TroVax Trial Approval

Jan. 10, 2001

PhotoCure Reports Skin Cancer Cures In Phase III PDT Trial

Jan. 10, 2001

PhotoCure Reports Skin Cancer Cures In Phase III PDT Trial

Jan. 10, 2001

Oxford BioMedica Moving To LSE Following TroVax Trial Approval

Jan. 10, 2001

Phytopharm Sees Encouraging Results In Phase I P54 Study

Jan. 10, 2001

View All Articles by Nuala Moran

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...